Agilent Plans to Buy Varian for $1.5 Billion to Expand Footprint in Life Sciences | GenomeWeb

This story originally ran on July 27 and has been updated to include additional comments.

By Tony Fong

Agilent Technologies continued to bet on the life-science sector on Monday, announcing it plans to spend $1.5 billion to purchase instrument and vacuum company Varian.

From a proteomics perspective, the purchase is not expected to have a profound effect on Agilent, even though Varian has a fleet of LC/MS and Fourier transform mass specs that have use in proteomics and protein analysis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.